CD105. also known as endoglin, is a transmembrane glycoprotein that serves as a co-receptor in the transforming growth factor-beta (TGF-β) signaling pathway. It is primarily expressed on proliferating vascular endothelial cells, making it a key marker for studying angiogenesis and vascular remodeling. CD105 plays a critical role in modulating cellular responses to TGF-β1 and TGF-β3. influencing processes such as cell adhesion, migration, and tissue morphogenesis. Its overexpression is associated with pathological angiogenesis in cancers, cardiovascular diseases, and inflammatory conditions.
CD105 antibodies are widely used in research and diagnostics to identify and isolate endothelial cells, particularly in tumor vasculature, where CD105 is upregulated. These antibodies enable the detection of microvessel density in tumor tissues, a prognostic indicator in oncology. Additionally, CD105-targeted imaging and therapeutic agents are under investigation for cancer treatment due to their potential to selectively target tumor blood vessels.
In immunology, CD105 antibodies aid in characterizing mesenchymal stromal cells (MSCs), as CD105 is a defining surface marker. Recent advances include the development of anti-CD105 monoclonal antibodies for experimental therapies, such as antibody-drug conjugates (ADCs) and immunotherapies aimed at inhibiting aberrant angiogenesis. Despite its prominence, CD105's dual role in pro- and anti-angiogenic signaling underscores the complexity of its biological functions, necessitating further research to optimize clinical applications.